Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study

NCT02853370 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.

NCT NCT02853370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02853370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2012
Completion date
December 31, 2020
Enrollment
78 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone b-cell lymphoma